1 / 9

ESA Dose Adjustment in Dialysis Patients: Implications for ESA Prescribing Information

ESA Dose Adjustment in Dialysis Patients: Implications for ESA Prescribing Information. Robert Provenzano, MD DaVita. Cohort-1 (Hb 12-13g/dl) Hemodialysis Patients Hb 12-13 g/dL end of month, December 2006 Level of dose decrease in January 2007 10-25%, 26-50%, 51-99%, or 100%

Rita
Télécharger la présentation

ESA Dose Adjustment in Dialysis Patients: Implications for ESA Prescribing Information

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ESA Dose Adjustment in Dialysis Patients: Implications for ESA Prescribing Information Robert Provenzano, MD DaVita

  2. Cohort-1 (Hb 12-13g/dl) Hemodialysis Patients Hb 12-13 g/dL end of month, December 2006 Level of dose decrease in January 2007 10-25%, 26-50%, 51-99%, or 100% Follow month-to-month Hb changes through June 2007 Cohort-2 (Hb >13g/dl) Hemodialysis Patients Hb > 13 g/dL end of month, December 2006 Level of dose decrease in January 2007 10-25%, 26-50%, 51-99%, or 100% Follow Hb changes through June 2007 Relationship between degree of dose reduction and Hb outcomes in patients with initial Hb 12-13 g/dL or Hb > 13 g/dL

  3. Holding Epoetin alfa when Hb is 12-13 g/dL increases relative risk of both low Hb early and high Hb later Source: DaVita internal data

  4. Holding at Hb > 13 increases risk of Hb < 11 early, > 13 late Source: DaVita internal data

  5. Larger epoetin dose reductions are associated with higher epoetin dose requirements Source: Data from Thamer M et al. JAMA 297 (15):1667-1674, 2007, Table 2.

  6. Better anemia management is also associated with higher epoetin dose requirements Source: Data from Thamer M et al. JAMA 297 (15):1667-1674, 2007, Table 2.

  7. Trend in Standardized Mortality Ratio (SMR) for all Dialysis Patients, 1985-2002 -19%

  8. AdministerEPOGEN® at the lowest dose needed to achieve a hemoglobin > 11g/dL. Decrease the EPOGEN® dose if the hemoglobin exceeds 12g/dL or the hemoglobin rate of rise exceeds 1g/dL per two weeks or 2g/dL per 4 weeks.

  9. Conclusions • Create Policies & warning specific to the CKD/ESRD population • Do not encourage withholding epoetin alfa as standard practice or making large dose decreases for Hb values above target: • Dangerous • Increases risk of early, serious anemia • Counterproductive • Increases risk of later, above-target Hb • May increase epoetin utilization • Current CMS regulations and Clinical Performance Measures • Are safe, sufficient, and well-supported by evidence • Do not underestimate or undervalue QOL…

More Related